Pierre michel Llorca

Professor

Université Clermont Auvergne

France

Research Interests

Explore related searches

Professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Pierre Michel Llorca is affiliated with the University of Clermont Auvergne in France. His research areas encompass precision psychiatry, treatment guidelines for tardive dyskinesia, and psychometric assessments in severe mental illness. He has contributed to recent articles focused on the efficacy of intranasal ketamine for major depressive disorder and the real-world effectiveness of antipsychotic treatments in schizophrenia.

Articles (14)

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (6)

Guillaume Fond

FRANCE

View details

emmanuel haffen

Prof. MD, PhD

Université de Franche-Comté

FRANCE

View details

Bruno Etain

Professor of Psychiatry

FRANCE

View details

vincent laprevote

Université de Lorraine

FRANCE

View details

Wissam El-Hage

Université de Tours

FRANCE

View details

Mark Edwards

Professor of Neurology and Interface Disorders

South London and Maudsley NHS Foundation Trust

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Pierre michel Llorca

Research Interests

Explore related searches

Contact this professor

About

Articles (14)

Construire la psychiatrie de précision : pourquoi et comment ?

Clinical practice guidelines for the treatment of tardive dyskinesia in Europe: A descriptive review

Psychometric Assessment of an Item Bank for Adaptive Testing on Patient-Reported Experience of Care Environment for Severe Mental Illness: Validation Study

Evolution of Cognitive Impairments in Treatment-Resistant Depression: Results from the Longitudinal French Centers of Expertise for Treatment-Resistant Depression (FACE-DR) Cohort

Development of the PREMIUM computerized adaptive testing for measuring the access and care coordination for patients with severe mental illness

How can we improve the care of patients with schizophrenia in the real-world? A population-based cohort study of 456,003 patients

Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders

Reducing Health Inequalities in Individuals with Severe Mental Disorders: Harnessing Real-World Data and Patient-Reported Measures

Selflife: A Life Skills Development Tool to Prevent Sexual Violence among Healthcare Students

The Efficacy and Safety of Intranasal Formulations of Ketamine and Esketamine for the Treatment of Major Depressive Disorder: A Systematic Review

Impact of the COVID-19 pandemic on non-COVID-19 hospital mortality in patients with schizophrenia: a nationwide population-based cohort study

Glutamatergic and N-Acetylaspartate Metabolites in Bipolar Disorder: A Systematic Review and Meta-Analysis of Proton Magnetic Resonance Spectroscopy Studies

Fifty years of experience with loxapine for the rapid non-coercive tranquilization of acute behavioral disturbances in schizophrenia patients, and beyond

Calibration and Validation of a PREMIUM-DT Item Bank to Measure the Experience of Drug Therapy for Patients with Severe Mental Illness

Collaborators (6)

Guillaume Fond

emmanuel haffen

Bruno Etain

vincent laprevote

Wissam El-Hage

Mark Edwards

Make your next move.